Amgen Inc (AMGN)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biologicssrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-14. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 10/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 2.61% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Amgen's Q3 2026 Earnings: What to Expect
- When Amgen's Forecast And Chart Say The Same Thing, Pay Attention
- Is Amgen Stock Increasing Your Market Risk?
- Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider
- What Could Amgen (AMGN) 70% Remission Trial Result Mean For Its Pipeline?
- VEEV Expands IQVIA Partnership With Clinical Operations Software Suite
- How to Turn $500,000 Into a Lazy $16,500 Yearly Passive Income Stream
- Bet on These Healthcare ETFs to Benefit From the Aging US Population
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Optimising clinical trial design choices in inflammatory bowel disease. — BMJ Open Gastroenterol 2026 Sep 22 PMID 42772941
- Genetic data sharing by clinical laboratories in Canada: A position statement by the Canadian College of Medical Geneticists. — Am J Hum Genet 2026 Sep 22 PMID 42772292
- Early Intraretinal Fluid Reduction is Linked to Vision Gains in Patients with Diabetic Macular Edema. — Ophthalmol Ther 2026 Sep 22 PMID 42771326
- Next-generation tumor-agnostic targets on the horizon. — Trends Cancer 2026 Sep 21 PMID 42767904
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0. — J Immunother Cancer 2026 Sep 21 PMID 42767771
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Amgen Inc.
Full AMGN Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.